Insider filing
Traded Nov 16 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 16, 2026 · Notice filed Nov 16, 2026
A Revolution Medicines officer told the SEC about a plan to sell $18.7M of Revolution Medicines shares around Nov 16, 2026. The filing says the shares were acquired as compensation. That is a tiny part of all Revolution Medicines shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider filing
Traded Nov 16 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Stephen Michael Kelsey (See Remarks) sold ~$1.92M of Revolution Medicines
Planned saleStephen Michael Kelsey (See Remarks) sold ~$608K of Revolution Medicines
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.